
Idiopathic pulmonary fibrosis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051122

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised nintedanib and pirfenidone for patients with idiopathic
pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis and listing dates

Idiopathic pulmonary fibrosis (IPF) is a chronic condition affecting the
lungs.

Listing dates are as follows:

-   nintedanib - 1 May 2017
-   pirfenidone - 1 July 2017

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item codes, restriction, the Pharmaceutical Benefits Scheme (PBS) and
the Services Australia websites.

Related links

Manage work items in Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
